Cargando…
P1696: ECONOMIC BURDEN IN CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) FOR PATIENTS WITH ≥2 PRIOR LINES OF THERAPY INCLUDING A BRUTON TYROSINE KINASE INHIBITOR (BTKI) AND/OR B-CELL LYMPHOMA 2 INHIBITOR (BCL2I)
| Autores principales: | , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Lippincott Williams & Wilkins
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10430214/ http://dx.doi.org/10.1097/01.HS9.0000973656.86771.99 |
| _version_ | 1785090907407646720 |
|---|---|
| author | Priyadarshini, Masoom Deshpande, Gaurav Tiwana, Simran K Le, T. Kim Garrison, Sean Awan, Farrukh |
| author_facet | Priyadarshini, Masoom Deshpande, Gaurav Tiwana, Simran K Le, T. Kim Garrison, Sean Awan, Farrukh |
| author_sort | Priyadarshini, Masoom |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-10430214 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2023 |
| publisher | Lippincott Williams & Wilkins |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-104302142023-08-17 P1696: ECONOMIC BURDEN IN CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) FOR PATIENTS WITH ≥2 PRIOR LINES OF THERAPY INCLUDING A BRUTON TYROSINE KINASE INHIBITOR (BTKI) AND/OR B-CELL LYMPHOMA 2 INHIBITOR (BCL2I) Priyadarshini, Masoom Deshpande, Gaurav Tiwana, Simran K Le, T. Kim Garrison, Sean Awan, Farrukh Hemasphere Posters Lippincott Williams & Wilkins 2023-08-08 /pmc/articles/PMC10430214/ http://dx.doi.org/10.1097/01.HS9.0000973656.86771.99 Text en Copyright © 2023 The Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access Abstract Book distributed under the Attribution-NonCommercial-NoDerivs (CC BY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) which allows third parties to download the articles and share them with others as long as they credit the author and the Abstract Book, but they cannot change the content in any way or use them commercially. |
| spellingShingle | Posters Priyadarshini, Masoom Deshpande, Gaurav Tiwana, Simran K Le, T. Kim Garrison, Sean Awan, Farrukh P1696: ECONOMIC BURDEN IN CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) FOR PATIENTS WITH ≥2 PRIOR LINES OF THERAPY INCLUDING A BRUTON TYROSINE KINASE INHIBITOR (BTKI) AND/OR B-CELL LYMPHOMA 2 INHIBITOR (BCL2I) |
| title | P1696: ECONOMIC BURDEN IN CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) FOR PATIENTS WITH ≥2 PRIOR LINES OF THERAPY INCLUDING A BRUTON TYROSINE KINASE INHIBITOR (BTKI) AND/OR B-CELL LYMPHOMA 2 INHIBITOR (BCL2I) |
| title_full | P1696: ECONOMIC BURDEN IN CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) FOR PATIENTS WITH ≥2 PRIOR LINES OF THERAPY INCLUDING A BRUTON TYROSINE KINASE INHIBITOR (BTKI) AND/OR B-CELL LYMPHOMA 2 INHIBITOR (BCL2I) |
| title_fullStr | P1696: ECONOMIC BURDEN IN CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) FOR PATIENTS WITH ≥2 PRIOR LINES OF THERAPY INCLUDING A BRUTON TYROSINE KINASE INHIBITOR (BTKI) AND/OR B-CELL LYMPHOMA 2 INHIBITOR (BCL2I) |
| title_full_unstemmed | P1696: ECONOMIC BURDEN IN CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) FOR PATIENTS WITH ≥2 PRIOR LINES OF THERAPY INCLUDING A BRUTON TYROSINE KINASE INHIBITOR (BTKI) AND/OR B-CELL LYMPHOMA 2 INHIBITOR (BCL2I) |
| title_short | P1696: ECONOMIC BURDEN IN CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) FOR PATIENTS WITH ≥2 PRIOR LINES OF THERAPY INCLUDING A BRUTON TYROSINE KINASE INHIBITOR (BTKI) AND/OR B-CELL LYMPHOMA 2 INHIBITOR (BCL2I) |
| title_sort | p1696: economic burden in chronic lymphocytic leukemia (cll) for patients with ≥2 prior lines of therapy including a bruton tyrosine kinase inhibitor (btki) and/or b-cell lymphoma 2 inhibitor (bcl2i) |
| topic | Posters |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10430214/ http://dx.doi.org/10.1097/01.HS9.0000973656.86771.99 |
| work_keys_str_mv | AT priyadarshinimasoom p1696economicburdeninchroniclymphocyticleukemiacllforpatientswith2priorlinesoftherapyincludingabrutontyrosinekinaseinhibitorbtkiandorbcelllymphoma2inhibitorbcl2i AT deshpandegaurav p1696economicburdeninchroniclymphocyticleukemiacllforpatientswith2priorlinesoftherapyincludingabrutontyrosinekinaseinhibitorbtkiandorbcelllymphoma2inhibitorbcl2i AT tiwanasimrank p1696economicburdeninchroniclymphocyticleukemiacllforpatientswith2priorlinesoftherapyincludingabrutontyrosinekinaseinhibitorbtkiandorbcelllymphoma2inhibitorbcl2i AT letkim p1696economicburdeninchroniclymphocyticleukemiacllforpatientswith2priorlinesoftherapyincludingabrutontyrosinekinaseinhibitorbtkiandorbcelllymphoma2inhibitorbcl2i AT garrisonsean p1696economicburdeninchroniclymphocyticleukemiacllforpatientswith2priorlinesoftherapyincludingabrutontyrosinekinaseinhibitorbtkiandorbcelllymphoma2inhibitorbcl2i AT awanfarrukh p1696economicburdeninchroniclymphocyticleukemiacllforpatientswith2priorlinesoftherapyincludingabrutontyrosinekinaseinhibitorbtkiandorbcelllymphoma2inhibitorbcl2i |